• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

    36.34 +1.22 (+3.47%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roivant Sciences Ltd. - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    Roivant Sciences Q1 Earnings Call Highlights ↗
    Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions... 
    Via MarketBeat
    Topics Earnings Government
    News headline image
    Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
    From Roivant Sciences
    Via GlobeNewswire
    ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗
    Via Chartmill
    News headline image
    Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗
    Wall Street expects sales to soar as several commercial launches approach. 
    Via The Motley Fool
    News headline image
    Roivant (ROIV) Q4 2025 Earnings Transcript ↗
    Roivant (ROIV) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Roivant Sciences Q4 Earnings Call Highlights ↗
    Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary... 
    Via MarketBeat
    Topics Earnings Government
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
    Via The Motley Fool
    News headline image
    Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
    Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
    This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
    Via The Motley Fool
    News headline image
    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
    The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
    This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials. 
    Via The Motley Fool
    News headline image
    Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
    In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗
    BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more... 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
    The news is likely to come as a relief to many investors, Citi told investors in a research note. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
    The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
    From Arbutus Biopharma Corporation
    Via GlobeNewswire
    News headline image
    Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
    From Roivant Sciences
    Via GlobeNewswire
    News headline image
    Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
    Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
    Via The Motley Fool
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗
    This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.